Myocarditis following COVID-19 vaccination in adolescents and adults: a cumulative experience of 2021

摘要

Abstract Clinical course and outcomes of myocarditis after COVID-19 vaccination remain variable. We retrospectively collected data on patients?>?12?years old from 01/01/2021 to 12/30/2021 who received COVID-19 messenger RNA (mRNA) vaccination and were diagnosed with myocarditis within 60?days of vaccination. Myocarditis cases were based on case definitions by authors. We report on 238 patients of whom most were male (n?=?208; 87.1). The mean age was 27.4?±?16 (range 12–80) years. Females presented at older ages (41.3?±?21.5?years) than men 25.7?±?14?years (p?=?0.001). In patients?>?20?years of age, the mean duration from vaccination to symptoms was 4.8?days?±?5.5?days, but in??20?years. Cardiogenic shock requiring mechanical circulatory support was seen and mortality was low. Future studies are needed to better evaluate risk factors, and long-term outcomes of COVID-19 mRNA vaccine myocarditis.